Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
1.
Autophagy ; 18(9): 2050-2067, 2022 09.
Article in English | MEDLINE | ID: mdl-34989311

ABSTRACT

Clostridioides difficile infection (CDI) is a common cause of nosocomial diarrhea. TcdB is a major C. difficile exotoxin that activates macrophages to promote inflammation and epithelial damage. Lysosome impairment is a known trigger for inflammation. Herein, we hypothesize that TcdB could impair macrophage lysosomal function to mediate inflammation during CDI. Effects of TcdB on lysosomal function and the downstream pro-inflammatory SQSTM1/p62-NFKB (nuclear factor kappa B) signaling were assessed in cultured macrophages and in a murine CDI model. Protective effects of two lysosome activators (i.e., vitamin D3 and carbamazepine) were assessed. Results showed that TcdB inhibited CTNNB1/ß-catenin activity to downregulate MITF (melanocyte inducing transcription factor) and its direct target genes encoding components of lysosomal membrane vacuolar-type ATPase, thereby suppressing lysosome acidification in macrophages. The resulting lysosomal dysfunction then impaired autophagic flux and activated SQSTM1-NFKB signaling to drive the expression of IL1B/IL-1ß (interleukin 1 beta), IL8 and CXCL2 (chemokine (C-X-C motif) ligand 2). Restoring MITF function by enforced MITF expression or restoring lysosome acidification with 1α,25-dihydroxyvitamin D3 or carbamazepine suppressed pro-inflammatory cytokine expression in vitro. In mice, gavage with TcdB-hyperproducing C. difficile or injection of TcdB into ligated colon segments caused prominent MITF downregulation in macrophages. Vitamin D3 and carbamazepine lessened TcdB-induced lysosomal dysfunction, inflammation and histological damage. In conclusion, TcdB inhibits the CTNNB1-MITF axis to suppress lysosome acidification and activates the downstream SQSTM1-NFKB signaling in macrophages during CDI. Vitamin D3 and carbamazepine protect against CDI by restoring MITF expression and lysosomal function in mice.Abbreviations: ATP6V0B: ATPase H+ transporting V0 subunit b; ATP6V0C: ATPase H+ transporting V0 subunit c; ATP6V0E1: ATPase H+ transporting V0 subunit e1; ATP6V1H: ATPase H+ transporting V1 subunit H; CBZ: carbamazepine; CDI: C. difficile infection; CXCL: chemokine C-X-X motif ligand; IL: interleukin; LAMP1: lysosomal-associated membrane protein 1; LC3: microtubule-associated protein 1 light chain 3; LEF: lymphoid enhancer binding factor 1; MITF: melanocyte inducing transcription factor; NFKB: nuclear factor kappa B; PMA: phorbol 12-myristate 13-acetate; TcdA: Clostridial toxin A; TcdB: Clostridial toxin B; TFE3: transcription factor E3; TFEB: transcription factor EB.


Subject(s)
Bacterial Toxins , Clostridioides difficile , Clostridium Infections , Vacuolar Proton-Translocating ATPases , Animals , Autophagy , Bacterial Proteins/metabolism , Bacterial Toxins/pharmacology , Carbamazepine/metabolism , Carbamazepine/pharmacology , Cholecalciferol/pharmacology , Clostridium Infections/metabolism , Hydrogen-Ion Concentration , Inflammation/metabolism , Lysosomes/metabolism , Macrophages/metabolism , Mice , NF-kappa B/metabolism , Sequestosome-1 Protein/metabolism , Vacuolar Proton-Translocating ATPases/metabolism
2.
Palliat Med ; 35(9): 1671-1681, 2021 Oct.
Article in English | MEDLINE | ID: mdl-33781119

ABSTRACT

BACKGROUND: Studies comparing end-of-life care between patients who are high cost users of the healthcare system compared to those who are not are lacking. AIM: The objective of this study was to describe and measure the association between high cost user status and several health services outcomes for all adults in Canada who died in acute care, compared to non-high cost users and those without prior healthcare use. SETTINGS AND PARTICIPANTS: We used administrative data for all adults who died in hospital in Canada between 2011 and 2015 to measure the odds of admission to the intensive care unit (ICU), receipt of invasive interventions, major surgery, and receipt of palliative care during the hospitalization in which the patient died. High cost users were defined as those in the top 10% of acute healthcare costs in the year prior to a person's hospitalization in which they died. RESULTS: Among 252,648 people who died in hospital, 25,264 were high cost users (10%), 112,506 were non-high cost users (44.5%) and 114,878 had no prior acute care use (45.5%). After adjustment for age and sex, high cost user status was associated with a 14% increased odds of receiving an invasive intervention, a 15% increased odds of having major surgery, and an 8% lower odds of receiving palliative care compared to non-high cost users, but opposite when compared to patients without prior healthcare use. CONCLUSIONS: Many patients receive aggressive elements of end-of-life care during the hospitalization in which they die and a substantial number do not receive palliative care. Understanding how this care differs between those who were previously high- and non-high cost users may provide an opportunity to improve end of life care for whom better care planning and provision ought to be an equal priority.


Subject(s)
Terminal Care , Adult , Cohort Studies , Hospitalization , Hospitals , Humans , Palliative Care , Retrospective Studies
3.
J Palliat Med ; 24(7): 1000-1010, 2021 07.
Article in English | MEDLINE | ID: mdl-33337265

ABSTRACT

Background: Much end-of-life care is provided in hospital, yet little is known about the delivery of palliative care during end-of-life hospitalizations. Objectives: To characterize the level of palliative care involvement across hospitalizations in the last year of life. Methods: A population-based retrospective cohort study of adults in Ontario, Canada, who died between April 1, 2012, and March 31, 2017, and had at least one acute care hospitalization in their last year of life. Using linked administrative health data, we developed a hierarchy of inpatient palliative care involvement reflecting the degree to which care was delivered with palliative intent. This hierarchy was based on palliative care diagnosis and service provider codes on hospitalization records and physician claims. We examined variations in the level of palliative care involvement across key patient characteristics. Results: In the last year of life, 65.1% of hospitalizations had no indication of palliative care involvement, 16.7% had a low level of involvement, 13.5% had a medium level of involvement, and 4.7% had a high level of involvement. Most hospitalizations with palliative care involvement (85.6%) occurred in the two months before death. Compared to patients who received no inpatient palliative care, patients who received a high level of palliative care involvement tended to be younger, died of cancer, resided in urban or lower income neighborhoods, and had fewer chronic conditions. Discussion: While many hospitalizations occurred in the last year of life, the majority did not involve palliative care, and very few had a high level of palliative care involvement.


Subject(s)
Palliative Care , Terminal Care , Adult , Cohort Studies , Hospitalization , Hospitals , Humans , Inpatients , Ontario , Retrospective Studies
4.
Emerg Microbes Infect ; 9(1): 631-638, 2020.
Article in English | MEDLINE | ID: mdl-32183606

ABSTRACT

Clostridioides difficile infection (CDI) is a common cause of nosocomial diarrhea and can sometimes lead to pseudo-membranous colitis and toxic megacolon. We previously reported that the PCR ribotype 002 was a common C. difficile ribotype in Hong Kong that was associated with increased mortality. In this study, we assessed in vitro bacteriological characteristics and in vivo virulence of ribotype 002 compared to other common ribotypes, including ribotypes 012, 014 and 046. We observed significantly higher toxin A (p < 0.05) and toxin B (p < 0.05) production, sporulation (p < 0.001) and germination rates (p < 0.0001) in ribotype 002 than other common ribotypes. In a murine model of C. difficile infection, ribotype 002 caused significantly more weight loss (p < 0.001) and histological damage (p < 0.001) than other common ribotypes. These findings may have contributed to the higher prevalence and mortality observed, and provided mechanistic insights that can help public surveillance and develop novel therapeutics to combat against this infection.


Subject(s)
Clostridiales/pathogenicity , Gram-Positive Bacterial Infections/microbiology , Animals , Hong Kong , Male , Mice, Inbred C57BL , Ribotyping , Virulence
5.
J Cell Mol Med ; 22(4): 2469-2477, 2018 04.
Article in English | MEDLINE | ID: mdl-29383879

ABSTRACT

Toxin B (TcdB) is a major pathogenic factor of Clostridum difficile. However, the mechanism by which TcdB exerts its cytotoxic action in host cells is still not completely known. Herein, we report for the first time that TcdB induced autophagic cell death in cultured human colonocytes. The induction of autophagy was demonstrated by the increased levels of LC3-II, formation of LC3+ autophagosomes, accumulation of acidic vesicular organelles and reduced levels of the autophagic substrate p62/SQSTM1. TcdB-induced autophagy was also accompanied by the repression of phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) complex 1 activity. Functionally, pharmacological inhibition of autophagy by wortmannin or chloroquine or knockdown of autophagy-related genes Beclin 1, Atg5 and Atg7 attenuated TcdB-induced cell death in colonocytes. Genetic ablation of Atg5, a gene required for autophagosome formation, also mitigated the cytotoxic effect of TcdB. In conclusion, our study demonstrated that autophagy serves as a pro-death mechanism mediating the cytotoxic action of TcdB in colonocytes. This discovery suggested that blockade of autophagy might be a novel therapeutic strategy for C. difficile infection.


Subject(s)
Autophagy/genetics , Bacterial Proteins/genetics , Bacterial Toxins/genetics , Clostridioides difficile/genetics , Clostridium Infections/therapy , Apoptosis/drug effects , Autophagosomes/drug effects , Autophagosomes/metabolism , Autophagosomes/microbiology , Autophagy-Related Protein 5 , Autophagy-Related Protein 7 , Bacterial Proteins/metabolism , Bacterial Toxins/metabolism , Beclin-1/genetics , Clostridioides difficile/pathogenicity , Clostridium Infections/genetics , Clostridium Infections/microbiology , Colon/cytology , Colon/microbiology , Humans , Phosphatidylinositol 3-Kinases/genetics , Phosphorylation , Sequestosome-1 Protein/genetics , TOR Serine-Threonine Kinases/genetics
6.
Sci Rep ; 7(1): 17218, 2017 12 08.
Article in English | MEDLINE | ID: mdl-29222426

ABSTRACT

Incidence of Clostridium difficile infection (CDI) is rapidly increasing and it poses a major health burden globally. However, data regarding the epidemiology of CDI in Asia are limited. We aimed to characterize the antimicrobial susceptibility patterns of common ribotypes of toxigenic C. difficile in Hong Kong. Fifty-three PCR ribotypes were identified among 284 toxigenic C. difficile clinical isolates. The five most prevalent ribotypes were 002 (13%), 017 (12%), 014 (10%), 012 (9.2%), and 020 (9.5%). All tested C. difficile strains remained susceptible to metronidazole, vancomycin, meropenem and piperacillin/tazobactam, but highly resistant to cephalosporins. Of the fluoroquinolones, highest resistance to ciprofloxacin was observed (99%), followed by levofloxacin (43%) and moxifloxacin (23%). The two newly emerged PCR ribotypes, 017 and 002, demonstrated high levels of co-resistance towards clindamycin, tetracycline, erythromycin and moxifloxacin. PCR ribotypes 017 and 002 with multi-drug resistance are rapidly emerging and continuous surveillance is important to monitor the epidemiology of C. difficile to prevent outbreaks of CDI.


Subject(s)
Anti-Bacterial Agents/pharmacology , Clostridioides difficile/classification , Clostridioides difficile/drug effects , Drug Resistance, Bacterial , Ribotyping , Clostridioides difficile/genetics , Hong Kong , Polymerase Chain Reaction
7.
Emerg Infect Dis ; 23(10): 1671-1679, 2017 10.
Article in English | MEDLINE | ID: mdl-28930010

ABSTRACT

Cross-sectional studies suggest an increasing trend in incidence and relatively low recurrence rates of Clostridium difficile infections in Asia than in Europe and North America. The temporal trend of C. difficile infection in Asia is not completely understood. We conducted a territory-wide population-based observational study to investigate the burden and clinical outcomes in Hong Kong, China, over a 9-year period. A total of 15,753 cases were identified, including 14,402 (91.4%) healthcare-associated cases and 817 (5.1%) community-associated cases. After adjustment for diagnostic test, we found that incidence increased from 15.41 cases/100,000 persons in 2006 to 36.31 cases/100,000 persons in 2014, an annual increase of 26%. This increase was associated with elderly patients, for whom incidence increased 3-fold over the period. Recurrence at 60 days increased from 5.7% in 2006 to 9.1% in 2014 (p<0.001). Our data suggest the need for further surveillance, especially in Asia, which contains ≈60% of the world's population.


Subject(s)
Clostridioides difficile/isolation & purification , Clostridium Infections/epidemiology , Cross Infection/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Clostridium Infections/microbiology , Clostridium Infections/mortality , Community-Acquired Infections , Cross Infection/microbiology , Cross Infection/mortality , Cross-Sectional Studies , Epidemiological Monitoring , Female , Hong Kong/epidemiology , Humans , Incidence , Male , Middle Aged , Recurrence , Survival Analysis
8.
Tuberculosis (Edinb) ; 98: 139-48, 2016 05.
Article in English | MEDLINE | ID: mdl-27156630

ABSTRACT

OBJECTIVES: To characterize at high resolution DNA methylation changes of cytokines which occur in the genome of macrophages in association with Mycobacterium tuberculosis (MTB) infection METHODS: We studied the methylation profiles of THP-1 derived macrophage cells infected with clinical MTB strains [Beijing/W & non-Beijing/W lineage, sensitive (INH(S), RIF(S)) & resistant (INH(R), RIF(R)) strains] and of host macrophages from MTB infected cohorts (active & latent patients) with the human methylation CpG islands microarrays. RESULTS: Methylated modification on the promoter sequences of cytokines and their receptors were found to be associated with MTB infection in a strain- and host-dependent manner. Our epigenetic analyses revealed that infection with Beijing/W MTB strains enhanced IL6R, IL4R and IL17R hyper-methylations in infected macrophages. Validation of IL6R methylated sequence confirmed that MTB infection induced DNA methylation of CpG67 region in the IL6R promoter. In addition, studies on the human macrophage methylation profiles from the patient cohorts indicated that the methylation rate of IL17 family members and related genes were significantly altered in patients with active MTB infections. CONCLUSIONS: Our study offered novel insights into the epigenetic changes in the interaction of host macrophages in MTB infections and warrant further explorations into these changes in modulating the immune response in active and latent MTB infections.


Subject(s)
Cytokines/genetics , DNA Methylation , Epigenesis, Genetic , Macrophages/microbiology , Mycobacterium tuberculosis/pathogenicity , Receptors, Interleukin/genetics , Tuberculosis/genetics , Tuberculosis/microbiology , Case-Control Studies , Cell Line , CpG Islands , Cytokines/metabolism , Host-Pathogen Interactions , Humans , Interleukin-4 Receptor alpha Subunit/genetics , Interleukin-4 Receptor alpha Subunit/metabolism , Latent Tuberculosis/genetics , Latent Tuberculosis/metabolism , Latent Tuberculosis/microbiology , Macrophages/metabolism , Promoter Regions, Genetic , Receptors, Interleukin/metabolism , Receptors, Interleukin-17/genetics , Receptors, Interleukin-17/metabolism , Receptors, Interleukin-6/genetics , Receptors, Interleukin-6/metabolism , Tuberculosis/metabolism
9.
Microb Drug Resist ; 22(7): 545-551, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27082669

ABSTRACT

The aim of this study is to investigate the mutation pattern of the folC gene in drug-resistant Mycobacterium tuberculosis (MTB) clinical isolates of global and Hong Kong cohorts. The public sequence read archives of 1,124 MTB genomes from three independent studies were retrieved and folC mutations existing solely in drug-resistant MTB strains were identified. A phylogenetic tree was constructed to analyze the segregation of mutation-related amino acid residues in the FolC structure. These mutation sites were further supported by direct Sanger sequencing of the folC gene among 254 clinical MTB isolates in a Hong Kong cohort. Homology modeling of wild-type and mutated FolC was performed, and the predicted structures were docked with hydroxydihydropteroate, the metabolic derivative of para-aminosalicylic acid (PAS), to evaluate the resultant binding affinity changes. Combining the results of three previous cohorts and our cohort, E40, I43, S150, and E153 are the most frequently affected amino acid residues in resistant isolates. Based on the distribution of mutations in the genome-based phylogenetic tree, lineage-specific mutation patterns were observed. Regarding the segregation of affected amino acid residues, the four most frequently affected residues are all in close proximity of the binding pocket for the PAS derivative. Molecular modeling results showed that mutations at E40, I43, and S150 can alter the structure of FolC putative binding pocket, causing the PAS derivative to bind outside of the now deformed pocket. This might ablate the interaction between the protein and the PAS derivative. To conclude, this study is the first comprehensive mutation pattern and bioinformatics analysis of the folC gene in MTB drug-resistant isolates. The distribution of mutations in phylogenetic lineages and protein structure is reported, analyzed, and discussed.


Subject(s)
Antitubercular Agents/chemistry , Bacterial Proteins/chemistry , Mutation , Mycobacterium tuberculosis/genetics , Peptide Synthases/chemistry , Pterins/chemistry , Antitubercular Agents/pharmacology , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Binding Sites , Computational Biology , Drug Resistance, Bacterial/genetics , Gene Expression , Genotype , Hong Kong , Humans , Microbial Sensitivity Tests , Molecular Docking Simulation , Mycobacterium tuberculosis/classification , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/enzymology , Peptide Synthases/genetics , Peptide Synthases/metabolism , Phylogeny , Protein Binding , Pterins/pharmacology , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Multidrug-Resistant/microbiology , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/microbiology
10.
PLoS One ; 10(6): e0126018, 2015.
Article in English | MEDLINE | ID: mdl-26053546

ABSTRACT

OBJECTIVES: The role of microRNAs in association with Mycobacterium tuberculosis (MTB) infection and the immunology regulated by microRNAs upon MTB infection have not been fully unravelled. We examined the microRNA profiles of THP-1 macrophages upon the MTB infection of Beijing/W and non-Beijing/W clinical strains. We also studied the microRNA profiles of the host macrophages by microarray in a small cohort with active MTB disease, latent infection (LTBI), and from healthy controls. RESULTS: The results revealed that 14 microRNAs differentiated infections of Beijing/W from non-Beijing/W strains (P<0.05). A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls. Pathway analyses of these differentially expressed miRNAs suggest that the immune-regulatory interactions involving TGF-ß signalling pathway take part in the dysregulation of critical TB processes in the macrophages, resulting in active expression of both cell communication and signalling transduction systems. CONCLUSION: We showed for the first time that the Beijing/W TB strains repressed a number of miRNAs expressions which may reflect their virulence characteristics in altering the host response. The unique signatures of 11 microRNAs may deserve further evaluation as candidates for biomarkers in the diagnosis of MTB and Beijing/W infections.


Subject(s)
Gene Expression Profiling , Gene Expression Regulation , Macrophages/metabolism , Macrophages/microbiology , MicroRNAs/genetics , Mycobacterium tuberculosis/physiology , Tuberculosis/genetics , Biomarkers/metabolism , Case-Control Studies , Cell Line , Cluster Analysis , Humans , Latent Tuberculosis/genetics , Latent Tuberculosis/microbiology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reproducibility of Results , Signal Transduction/genetics , Tuberculosis/microbiology
11.
Int J STD AIDS ; 25(3): 193-200, 2014 Mar.
Article in English | MEDLINE | ID: mdl-23970651

ABSTRACT

Seventy-two adult Chinese HIV-positive treatment-naïve patients were recruited in a study to evaluate prospectively the associations between CYP2B6 516 G/T polymorphisms and sleep quality following treatment with an efavirenz-based regimen. Overall, the patients gave an allelic frequency of 0.3 for CYP2B6 516 T, and a genotype frequency of 9.4% for TT. Compared to GG, GT gave a higher median value of plasma efavirenz level at four weeks (3.77 mg/L vs 2.59 mg/L, p < 0.001) and 12 months (3.57 mg/L vs 2.97 mg/L, p = 0.026). Using generalised estimating equations analysis to track the variance over time, there was poorer Pittsburgh Sleep Quality Index in GT compared to GG, while GT was associated with a higher efavirenz level of >4 mg/L. There was however no difference in the component sleep scores nor was there direct association between sleep quality and plasma efavirenz levels. The results suggested that CYP2B6 genotype was associated with different patterns of sleep problems, further investigation of which is warranted with the objective of optimizing therapy with efavirenz-based regimens.


Subject(s)
Anti-HIV Agents/blood , Aryl Hydrocarbon Hydroxylases/genetics , Benzoxazines/blood , HIV Infections/drug therapy , Polymorphism, Genetic/genetics , Sleep/physiology , Adult , Alkynes , Alleles , Anti-HIV Agents/adverse effects , Anti-HIV Agents/therapeutic use , Asian People/genetics , Benzoxazines/adverse effects , Benzoxazines/therapeutic use , Cyclopropanes , Cytochrome P-450 CYP2B6 , Female , Genotype , HIV Infections/blood , HIV Infections/genetics , Humans , Male , Middle Aged , Pharmacogenetics , Prospective Studies , Quality of Life , Reverse Transcriptase Inhibitors/therapeutic use , Sleep/drug effects , Surveys and Questionnaires , Treatment Outcome
12.
J Clin Microbiol ; 51(10): 3308-13, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23903542

ABSTRACT

Clostridium difficile infection is almost unrecognized in mainland China. We have undertaken a study in a large Chinese teaching hospital in Changsha, Hunan, China, to identify cases of C. difficile, record patient characteristics, and define the molecular epidemiology with respect to ribotype distribution and cross-infection. Between April 2009 and February 2010, we examined fecal samples from 70 hospitalized patients with diarrhea who were receiving or had received antibiotics within the previous 6 weeks. Clinical information was collected and the samples were cultured for C. difficile retrospectively. Isolates were ribotyped, and multiple-locus variable-number tandem-repeat assay (MLVA) subtyping was performed on clusters of the same ribotype. The mean age of patients from whom C. difficile was cultured was 58 years, with only 4/21 patients aged >65 years. All patients, with a single exception, had received a third-generation cephalosporin and/or a quinolone antibiotic. Twenty-one isolates of C. difficile were recovered, and seven different ribotypes were identified, the dominant types being 017 (48%), 046 (14%), and 012 (14%). We identified two clusters of cross-infection with indistinguishable isolates of ribotype 017, with evidence of spread both within and between wards. We have identified C. difficile as a possibly significant problem, with cross-infection and a distinct ribotype distribution, in a large Chinese hospital. C. difficile may be underrecognized in China, and further epidemiological studies across the country together with the introduction of routine diagnostic testing are needed to ascertain the size of this potentially significant problem.


Subject(s)
Clostridioides difficile/classification , Clostridioides difficile/isolation & purification , Clostridium Infections/epidemiology , Cross Infection/epidemiology , Diarrhea/epidemiology , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Asia , China/epidemiology , Clostridioides difficile/genetics , Clostridium Infections/microbiology , Cluster Analysis , Cross Infection/microbiology , Diarrhea/microbiology , Feces/microbiology , Female , Genotype , Hospitals , Humans , Male , Middle Aged , Minisatellite Repeats , Molecular Epidemiology , Ribotyping
13.
Antimicrob Agents Chemother ; 57(7): 3445-9, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23650165

ABSTRACT

We evaluated treatment with linezolid, dosed at 800 mg once daily for 1 to 4 months as guided by sputum culture status and tolerance and then at 1,200 mg thrice weekly until ≥ 1 year after culture conversion, in addition to individually optimized regimens among 10 consecutive patients with extensively drug-resistant tuberculosis or fluoroquinolone-resistant multidrug-resistant tuberculosis. All achieved stable cure, with anemia corrected and neuropathy stabilized, ameliorated, or avoided after switching to intermittent dosing. Serum linezolid profiles appeared better optimized.


Subject(s)
Acetamides/administration & dosage , Antitubercular Agents/administration & dosage , Mycobacterium tuberculosis/drug effects , Oxazolidinones/administration & dosage , Tuberculosis, Multidrug-Resistant/drug therapy , Acetamides/therapeutic use , Adult , Antitubercular Agents/therapeutic use , Drug Administration Schedule , Female , Humans , Linezolid , Male , Middle Aged , Oxazolidinones/therapeutic use , Sputum/microbiology , Treatment Outcome , Young Adult
15.
PLoS One ; 7(2): e31312, 2012.
Article in English | MEDLINE | ID: mdl-22359586

ABSTRACT

Sophora flavescens is a Chinese medicinal herb used for the treatment of gastrointestinal hemorrhage, skin diseases, pyretic stranguria and viral hepatitis. In this study the herb-drug interactions between S. flavescens and indinavir, a protease inhibitor for HIV treatment, were evaluated in rats. Concomitant oral administration of Sophora extract (0.158 g/kg or 0.63 g/kg, p.o.) and indinavir (40 mg/kg, p.o.) in rats twice a day for 7 days resulted in a dose-dependent decrease of plasma indinavir concentrations, with 55%-83% decrease in AUC(0-∞) and 38%-78% reduction in C(max). The CL (Clearance)/F (fraction of dose available in the systemic circulation) increased up to 7.4-fold in Sophora-treated rats. Oxymatrine treatment (45 mg/kg, p.o.) also decreased indinavir concentrations, while the ethyl acetate fraction of Sophora extract had no effect. Urinary indinavir (24-h) was reduced, while the fraction of indinavir in faeces was increased after Sophora treatment. Compared to the controls, multiple dosing of Sophora extract elevated both mRNA and protein levels of P-gp in the small intestine and liver. In addition, Sophora treatment increased intestinal and hepatic mRNA expression of CYP3A1, but had less effect on CYP3A2 expression. Although protein levels of CYP3A1 and CYP3A2 were not altered by Sophora treatment, hepatic CYP3A activity increased in the Sophora-treated rats. All available data demonstrated that Sophora flavescens reduced plasma indinavir concentration after multiple concomitant doses, possibly through hepatic CYP3A activity and induction of intestinal and hepatic P-gp. The animal study would be useful for predicting potential interactions between natural products and oral pharmaceutics and understanding the mechanisms prior to human studies. Results in the current study suggest that patients using indinavir might be cautioned in the use of S. flavescens extract or Sophora-derived products.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/physiology , Cytochrome P-450 CYP3A/physiology , Herb-Drug Interactions , Indinavir/pharmacokinetics , Plant Preparations/pharmacokinetics , Sophora , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Administration, Oral , Animals , Cytochrome P-450 CYP3A/genetics , Herbal Medicine/methods , Indinavir/administration & dosage , Indinavir/blood , Plant Preparations/blood , RNA, Messenger/analysis , Rats
16.
J Clin Microbiol ; 49(7): 2509-15, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21593264

ABSTRACT

Rapid diagnosis and genotyping of Mycobacterium tuberculosis by molecular methods are often limited by the amount and purity of DNA extracted from body fluids. In this study, we evaluated 12 DNA extraction methods and developed a highly sensitive protocol for mycobacterial DNA extraction directly from sputa using surface-coated magnetic particles. We have also developed a novel multiplex real-time PCR for simultaneous identification of M. tuberculosis complex and the Beijing/W genotype (a hypervirulent sublineage of M. tuberculosis) by using multiple fluorogenic probes targeting both the M. tuberculosis IS6110 and the Rv0927c-pstS3 intergenic region. With reference strains and clinical isolates, our real-time PCR accurately identified 20 non-Beijing/W and 20 Beijing/W M. tuberculosis strains from 17 different species of nontuberculosis Mycobacterium (NTM). Further assessment of our DNA extraction protocol and real-time PCR with 335 nonduplicate sputum specimens correctly identified all 74 M. tuberculosis culture-positive specimens. In addition, 15 culture-negative specimens from patients with confirmed tuberculosis were also identified. No cross-reactivity was detected with NTM specimens (n = 31). The detection limit of the assay is 10 M. tuberculosis bacilli, as determined by endpoint dilution analysis. In conclusion, an optimized DNA extraction protocol coupled with a novel multiprobe multiplex real-time PCR for the direct detection of M. tuberculosis, including Beijing/W M. tuberculosis, was found to confer high sensitivity and specificity. The combined procedure has the potential to compensate for the drawbacks of conventional mycobacterial culture in routine clinical laboratory setting, such as the lengthy incubation period and the limitation to viable organisms.


Subject(s)
DNA, Bacterial/isolation & purification , Mycobacterium tuberculosis/classification , Mycobacterium tuberculosis/isolation & purification , Polymerase Chain Reaction/methods , Specimen Handling/methods , Sputum/microbiology , Tuberculosis/diagnosis , Adult , Aged , Cross Reactions , DNA Transposable Elements , DNA, Bacterial/genetics , DNA, Intergenic , Female , Genotype , Humans , Male , Middle Aged , Mycobacterium tuberculosis/genetics , Sensitivity and Specificity , Time Factors , Tuberculosis/microbiology
17.
J Antimicrob Chemother ; 65(8): 1551-61, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20542907

ABSTRACT

OBJECTIVES: Multidrug-resistant tuberculosis has emerged as a global health threat. Given poor treatment outcomes of fluoroquinolone-resistant multidrug-resistant tuberculosis, there is a pressing need for rapid drug susceptibility testing of multidrug-resistant Mycobacterium tuberculosis against fluoroquinolones. This review aims at evaluating these rapid assays. METHODS: PubMed and OvidSP were used to search MEDLINE and EMBASE for publications in English regarding rapid assays that tested ofloxacin, levofloxacin or moxifloxacin. Studies were included only in the concurrent presence of sensitivity and specificity data. Summary estimates of sensitivity and specificity were generated by the bivariate random effects model when there were at least three sets of data under the same assay category that tested the same fluoroquinolone with reference to a standard test. RESULTS: Of 108 articles identified, 24 articles were included in a meta-analysis of rapid assays that tested ofloxacin in culture isolates. Overall, rapid genotypic assays targeting gyrA only are significantly less specific (96% versus 99%) and non-significantly less sensitive (88% versus 94%) than rapid phenotypic assays. To test for the presence or absence of ofloxacin resistance to a certainty threshold of 90%, the required pre-test prevalence ranges of ofloxacin resistance for genotypic assays targeting gyrA only are 29%-47% overall, 36%-55% for PCR-DNA sequencing and 23%-44% for others. Corresponding ranges are 7%-65% for phenotypic assays overall and 3%-75% for Mycobacteria Growth Indicator Tube (MGIT). CONCLUSIONS: Assuming that the mean pre-test prevalence of fluoroquinolone resistance in culture isolates of multidrug-resistant M. tuberculosis is approximately 20%, rapid genotypic assays other than PCR-DNA sequencing, targeting gyrA only, can reliably screen for ofloxacin resistance.


Subject(s)
Antitubercular Agents/pharmacology , Fluoroquinolones/pharmacology , Mycobacterium tuberculosis/drug effects , Tuberculosis, Multidrug-Resistant/diagnosis , Aza Compounds/pharmacology , Bacterial Proteins/genetics , DNA Gyrase/genetics , DNA, Bacterial/genetics , Drug Resistance, Multiple, Bacterial , Genotype , Humans , Levofloxacin , Microbial Sensitivity Tests/methods , Moxifloxacin , Mycobacterium tuberculosis/isolation & purification , Ofloxacin/pharmacology , Quinolines/pharmacology , Sensitivity and Specificity , Tuberculosis, Multidrug-Resistant/microbiology
18.
Antimicrob Agents Chemother ; 54(3): 1082-93, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20086164

ABSTRACT

This study aimed at elucidating the physiological basis of bacterial antibiotic tolerance. By use of a combined phenotypic and gene knockout approach, exogenous nutrient composition was identified as a crucial environmental factor which could mediate progressive development of tolerance with markedly varied drug specificity and sustainability. Deprivation of amino acids was a prerequisite for tolerance formation, conferring condition-specific phenotypes against inhibitors of cell wall synthesis and DNA replication (ampicillin and ofloxacin, respectively), according to the relative abundances of ammonium salts, phosphate, and nucleobases. Upon further depletion of glucose, this variable phase consistently evolved into a sustainable mode, along with enhanced capacity to withstand the effect of the protein synthesis inhibitor gentamicin. Nevertheless, all phenotypes produced during spontaneous nutrient depletion lacked the sustainable, multidrug-tolerant features exhibited by the stationary-phase population and were attributed to complex interaction between starvation-mediated metabolic and stress protection responses on the basis of the following reasons: (i) the nutrition-dependent tolerance characteristics observed suggested that adaptive biosynthetic mechanisms could suppress but not fully avert tolerance under transient starvation conditions; (ii) formation of specific phenotypes could be inhibited by suppressing protein synthesis prior to nutrient depletion; (iii) bacteriostatic drugs produced only weak tolerance in the absence of starvation signals; and (iv) the attenuation of the stringent and SOS responses, as well as the functionality of other putative tolerance determinants, including rpoS, hipA, glpD, and phoU, could alter the induction requirement and drug specificity of the resultant phenotypes. These data reveal the common physiological grounds characteristic of starvation responses and the onset of antibiotic tolerance in bacteria.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Tolerance , Escherichia coli K12/drug effects , Escherichia coli K12/physiology , Heat-Shock Response , Culture Media/chemistry , Escherichia coli K12/genetics , Escherichia coli K12/growth & development , Escherichia coli Proteins/genetics , Escherichia coli Proteins/metabolism , Gene Expression Regulation, Bacterial , Microbial Sensitivity Tests
20.
J Antimicrob Chemother ; 63(2): 295-301, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19095682

ABSTRACT

OBJECTIVES: Since the emergence of multidrug-resistant and extensively drug-resistant tuberculosis, there has been a call for a rapid assay to detect rifampicin-resistant strains that can be implemented into a routine service to analyse all strains in a specific geographical location. Denaturing HPLC (dHPLC) is a rapid screening test that can detect mutations in PCR amplicons. The aim of this study was to evaluate the dHPLC analysis of rifampicin-resistant Mycobacterium tuberculosis isolates using an extensive strain collection from Hong Kong and the UK and a collection of 84 consecutive clinical isolates. METHODS: DNA from 51 rifampicin-resistant M. tuberculosis strains from the UK and Hong Kong identified from 1996 to 2005 was extracted and each mutation was defined by capillary electrophoresis. A 400 bp PCR product was amplified from each strain, heteroduplexed with a known susceptible control (H37Rv) and analysed by dHPLC at 67.0 degrees C. RESULTS: Forty-five out of 51 (88.2%) rifampicin-resistant strains with known DNA mutations were detected by dHPLC. Two out of 84 clinical isolates were phenotypically rifampicin-resistant and dHPLC detected a mutation in the rpoB amplicon for both these isolates. dHPLC detected a mutation in 1 out of 82 phenotypically rifampicin-susceptible isolates (M482T, a non-cluster I/II mutation). In a combined analysis of all strains and isolates, mutation detection by dHPLC analysis exhibited 88.2% sensitivity and 98.8% specificity. CONCLUSIONS: This study shows that dHPLC analysis is sensitive and specific and could be implemented in a routine clinical service.


Subject(s)
Antitubercular Agents/pharmacology , Chromatography, High Pressure Liquid , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/genetics , Nucleic Acid Denaturation , Rifampin/pharmacology , Bacterial Proteins/genetics , DNA, Bacterial/genetics , DNA-Directed RNA Polymerases , Drug Resistance, Bacterial , Electrophoresis, Capillary , Hong Kong , Humans , Microbial Sensitivity Tests/methods , Mutation, Missense , Mycobacterium tuberculosis/isolation & purification , Polymerase Chain Reaction , Sensitivity and Specificity , Tuberculosis/microbiology , United Kingdom
SELECTION OF CITATIONS
SEARCH DETAIL
...